ONCOLOGY · FOR SPONSORS
BRCR Global brings a distinctive oncology research model that combines patient access, therapeutic experience, operational infrastructure, and a strong culture of quality.
We understand that oncology studies are different from many other therapeutic areas. They require careful patient identification, close collaboration with treating physicians, protocol-specific clinical review, sensitivity in communication, and strong coordination across multiple teams.
Our oncology network is designed to support these needs through a multidisciplinary model that integrates investigators, coordinators, recruitment teams, quality oversight, regulatory support, and community/physician engagement.
Specialized Oncology Experience
Our network has experience supporting oncology and hematology studies across multiple indications, patient profiles, and protocol complexities.
Patient-Centered Execution
We recognize the emotional and clinical sensitivity of oncology research. Our teams prioritize respect, clarity, support, and communication throughout the patient journey.
Strong Recruitment & Referral Strategy
We combine EMR review, physician referrals, oncology networks, medical outreach, community education, and pre-screening workflows to identify potential candidates.
Operational Agility
Our teams are structured to respond quickly to sponsor needs, patient opportunities, protocol changes, site questions, and recruitment challenges.
Multidisciplinary Coordination
Oncology trials often require coordination among investigators, referring physicians, nurses, coordinators, imaging, labs, pharmacy, quality, and regulatory teams. BRCR Global supports this integration.
Quality-Driven Approach
Oncology protocols demand accuracy, documentation, safety awareness, and strict adherence to requirements. Quality is embedded into our operational model.
Regional Reach
Our site network and alliances across the Americas help sponsors and CROs access diverse patient populations and strategic oncology capabilities.
BRCR Global offers more than site participation. We provide an oncology execution model designed for complex protocols, specialized populations, and measurable performance.
